Rimonabant Acomplia is an oral anti-obesity treatment which is developed by French pharmaceutical firm, Sanofi-Aventis. Acomplia with Rimonabant as its active component is a consequence of 2 years of clinical trials.

CB-1 receptors which are situated in the Endo-Cannabinoid System are responsible for regulating appetite in the body. Rimonabant Acomplia is formulated in such a manner that its usage targets these receptors, which hinders their over activity thereby causing loss of appetite. Loss of appetite is beneficial in reducing your daily intake of food, which would be then consequential in trimming down of excessive bodily weight.

Usage of Rimonabant Acomplia diet pill is suggested to be taken in consonance with a balanced diet and a regular workout strategy to fetch effective weight loss results. Zimulti is a trade name which has been decided for Rimonabant Acomplia’s launch in the US after receiving FDA approval. Weight loss medication Rimonabant Acomplia has already been approved for sale in several European and Latin- American countries.

Prior to initiating usage of Rimonabant Acomplia it is recommended to procure a prescription from a doctor to attain optimistic weight loss results. Its usage is not meant for use if you are a pregnant woman, nursing mother, heart patient, diabetic or an individual under the age group of 18 years. Discuss your medical record both previous and current so as to help the doctor ascertain the suitability of this weight loss medication in accordance to your specific medical conditions.